_________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________
Cosentyx is indicated for the treatment of: moderate to severe plaque psoriasis (PsO) in adults, adolescents and children from the age of 6 years who are candidates for systemic therapy; active psoriatic arthritis in adult patients, alone or in combination with MTX, when the response to previous DMARD therapy has been inadequate; active ankylosing spondylitis in adults who have responded inadequately to conventional therapy; active non-radiographic axial spondyloarthritis with objective signs of inflammation as indicated by elevated CRP and/or MRI evidence in adults who have responded inadequately to NSAIDs.
Click here for Cosentyx®(secukinumab) prescribing information
Want to be notified of upcoming webinars?
Click the button below
BAD, British Association of Dermatologists; BADBIR, British Association of Dermatologists Biologics and Immunomodulators Register; DMARD, disease-modifying anti-rheumatic drug; IGA 0/1, investigator’s global assessment; MTX, methotrexate; NSAID, non-steroidal anti-inflammatory drug; PASI 90, psoriasis area and severity index; Q2W, every 2 weeks; Q4W, every 4 weeks.
